<i>SMPD1</i> mutations, activity, and α‐synuclein accumulation in Parkinson's diseaseRoy N. Alcalay, Ziv Gan‐Or, Benoît Vanderperre et al.|Movement Disorders|2019Cited by 117
Pharmacological Inhibition of Brain EGFR Activation By a BBB-penetrating Inhibitor, AZD3759, Attenuates α-synuclein Pathology in a Mouse Model of α-Synuclein PropagationOmid Tavassoly, Edward A. Fon|Neurotherapeutics|2021Cited by 26